Related Experiment Videos
[Oral immunotherapy in oculorhinitis from Gramineae]
M L Pacor1, D Biasi, A Carletto
1Istituto di Clinica Medica, Università, Verona.
Recenti Progressi in Medicina
|January 1, 1996
Summary
Oral immunotherapy effectively reduced symptoms and antihistamine use in patients with grass pollen-induced allergic rhinoconjunctivitis. This grass pollen immunotherapy treatment was well-tolerated over two years.
Area of Science:
- Allergy and Immunology
- Immunotherapy
- Ophthalmology
Context:
- Seasonal allergic rhinoconjunctivitis (SAR) affects numerous individuals globally.
- Grass pollen is a common trigger for SAR, leading to significant symptom burden.
- Traditional treatments include antihistamines and subcutaneous immunotherapy.
Purpose:
- To evaluate the efficacy and tolerability of oral immunotherapy (OIT) for grass pollen SAR.
- To compare OIT outcomes with historical data or placebo (implied).
Summary:
- 34 patients with grass pollen SAR received OIT for two years.
- Diagnosis confirmed via history, Skin Prick Test, and RAST.
- Treatment involved escalating daily allergen doses, then twice-weekly maintenance.
- Significant reduction in symptom severity and antihistamine consumption observed.
- No adverse effects reported, indicating good tolerability.
Impact:
- Oral immunotherapy presents a safe and effective alternative to subcutaneous immunotherapy for grass pollen SAR.
- This study supports OIT as a viable treatment option for allergic rhinoconjunctivitis.
- Findings may influence clinical guidelines for managing seasonal allergies.